MedTrace Logo

SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer

NCT07256236 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2026-03-30

No results posted yet for this study

Summary

This study is a prospective, single arm II clinical trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (SKB264) and QL1706 in the treatment of recurrent or metastatic cervical cancer.

Conditions

Interventions

DRUG

Sacituzumab tirumotecan

intravenous (IV) infusion (4mg/kg, Q2W)

DRUG

QL1706

intravenous (IV) infusion (3mg/kg, Q2W). Continuous administration will be maintained until radiological disease progression, occurrence of intolerable toxicity, the participant requests to discontinue treatment, or other treatment discontinuation criteria specified in the protocol are met (whichever occurs first). The maximum duration of administration for QL1706 is 24 months.

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-28
Primary Completion
2028-06-30
Completion
2028-12-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07256236 on ClinicalTrials.gov